Trade ideas
GILD: Sort opportunityAn intraday high potential, Back Tested Sort Analysis.
We ll try to enter into the correction of the uptrend movement.
DETAILS ON THE CHART
NOTE: Entry range area above the entry point, is calculated upon 80% of the recorded pullback back tested past performances
DISCLAIMER: This is a technical analysis study, not an advice or recommendation to invest money on.
GILD for a Long PlayShares of GILD have recently broken out above resistance around $74 and have since successfully tested and held it as support (dashed green line) on two different occasions.
They look destined to at least test the falling trend line (red line), and I think there's a good chance we break through that resistance to establish a new trend higher.
I'm a buyer via calls, specifically the November $80 calls because they will carry me through the next earnings report. That's not to say I'll hold them through the release, but I suspect premiums will elevate leading in to the report and that should help bolster the bullish position.
GILD: No such thing as Double Bottoms? Im a Rookie so dont hateOn weekly chart seeing a trend line from the high as strong resistance and has 2 touches and looks like might be a 3rd to confirm it. Also, on TD the count is on 8 which means we should see a slow down which gives me more faith in the trend line. The Daily on the TD is on a corrective sate completing a 9 and into couple days of correction so i think it coincides with the weekly, we should see another 9 days of up and then should run into the weekly 9 and then another correction.
My thoughts is it touches the trend @ 78.60 ish goes down to test support @64 and then a decision is made if it holds or breaks.
Gilead Sciences: fighting competitive headwinds?One of the things that analysts are watching out for is the impact of patent expirations on the company's revenue and margin. Gilead's HIV franchise saw the first important patent expirations in 2017, and the firm needs to convert patients to newer products like Genvoya and Biktarvy to avoid a significant hit to sales.
Gilead generates stellar profit margins with its HIV and HCV portfolio, which requires only a small salesforce and inexpensive manufacturing. What Gilead needs to drive business further is HCV market stabilization, strong continued innovation in HIV, solid pipeline data, and smart future acquisitions to return to growth.
www.finstead.com
GILD - wave 5 in progressIf this is not a perfect demonstration of Elliott Wave Theory, I don't know what else would be.
- Wave 2 measures exactly 61.8% of wave 1
- Wave 3 is exactly at 161.8% of 1
- Wave 4 is exactly at 38.2% of wave 3.
- Inside zigzag 4, c is exactly 123.6% of a.
- Plus the yellow resistance box failed to break out.
- Plus OBV was going no where when price moved from 64 to 72 (labeled as 4).
It looks like wave i of 5 is forming as a leading diagonal and not a bullish flag (in which case resistance will be broken and stop loss will need to trigger).
Stop loss can be placed very tightly at 72.50
Traditional target for wave 5 is just below 60.
GILD - Stock falling to 57 handleSetup:
It was noted that GILD could be dropping to 73.878
Our setup is complemented by the following:
1. Multiple timeframe analysis
2. Divergence
Approach:
Our trade strategy is as follow: We will open two consecutive trades, they will both have the same stop loss but different take profits.
Trade 1:
Entry: 71.94
SL: 74.35
TP: 62.39
Entry: 71.94
SL: 74.35
TP: 57.46
It should be noted that once TP1 is hit, we will move the stop loss of trade 2 to breakeven.
Risk & Reward:
Total Risk:
2%
Total Reward:
10.2%
Good Luck :-)






















